J. Pintor et al., SELECTIVITY AND ACTIVITY OF ADENINE DINUCLEOTIDES AT RECOMBINANT P2X(2) AND P2Y(1) PURINOCEPTORS, British Journal of Pharmacology, 119(5), 1996, pp. 1006-1012
1 Adenine dinucleotides (Ap(x)A, x=2-6) are naturally-occurring polyph
osphated nucleotidic substances which are found in the CNS and are kno
wn to be released in a calcium-dependent manner from storage vesicles
in brain synaptosomes. The selectivity and activity of adenine dinucle
otides for neuronally-derived recombinant P-2 purinoceptors were studi
ed using P2x(2) and P2Y(1) subtypes expressed in Xenopus oocytes. 2 Fo
r the P2Y(1) subtype derived from chick brain, Ap(3)A was equipotent a
nd as active as ATP (EC(50) values: 375+/-86 nM and 334+/-25 nM, respe
ctively). Ap4A was a weak partial agonist and other dinucleotides were
inactive as agonists, None of the inactive dinucleotides were antagon
ists nor modulated the acitivity of Ap(3)A and ATP. 3 For the P2X(2) s
ubtype derived from rat PCl2 cells, Ap(4)A was as active as ATP but le
ss potent (EC(50) values: 15.2+/-1 mu M and 3.7+/-0.7 mu M, respective
ly). Other adenosine dinucleotides were inactive as either agonists or
antagonists. 4 Ap(5)A (1-100 nM) potentiated ATP-responses at the P2x
(2) subtype, showing an EC(50) of 2.95+/-0.7 nM for this modulatory ef
fect. Ap(5)A (10 nM) shifted the concentration-response curves for ATP
to the left by one-half log(10) unit but did not alter the Hill co-ef
ficient for ATP (n(H)=2.1+/-0.1). Ap(5)A (10 nM) failed to potentiate
Ap(4)A-responses but did enhance the efficacy of the Pt purinoceptor a
ntagonist, suramin, by 12 fold at the P2x(2) subtype. 5 In conclusion,
the results show that ionotropic (P2x(2)) and metabotropic (P2Y(1)) A
TP receptors which occur in the CNS are activated selectively by natur
ally-occurring adenine dinucleotides which are known to be released wi
th nucleotides from storage vesicles. The observed potentiation of P2x
(2)-responses by Ap(5)A, where co-released with ATP by brain synaptoso
mes, may have a functional bearing in purinergic signalling in the CNS
.